Injectable Drug Delivery Resources

  1. Development Of Next Gen Sustained Release Solutions For Pain Management 2/22/2023

    A TheraPEA™ polymer based injectable formulation designed to deliver the same dose of Triamcinolone Acetonide (TAA) as in Zilretta® has shown promising results in a series of pre-clinical studies.

  2. Safeguarding Cell Therapy Cryopreservation: Primary Containers 5/20/2024

    Review different aspects of container selection from the perspective of cryopreservation that are may be overlooked but critical for the quality of cell therapy drug products.

  3. A Technical Package That Serves On-Time Injectable Project Completion 4/24/2023

    The accuracy, robustness, and completeness of the technical package an organization submits to its development and/or manufacturing partner is critical to meeting fill project timelines.

  4. Annex 1 – The Brave New World Of Regulatory Compliance 2/3/2023

    The revision to Annex 1 will become effective in August 2023. Explore the major changes and considerations along with the next steps to achieve Annex 1 Regulatory compliance.

  5. Overcoming Challenges In Cell And Gene Therapy Containment

    Review the hurdles that can slow your time to market, including the challenges in packaging high-value therapies and solutions to help you mitigate risk and simplify the journey.

  6. Flexible Manufacturing With Adaptable Assembly And Intelligent Software 7/1/2026

    Shift from static lines to modular assembly. Combining intelligent software with plug-and-play hardware enables rapid format changes, shortens validation, and unlocks data for scalability.

  7. How To Protect A Modern Silicone Oil-Sensitive Biologic Drug For Self-Injection Of 2.25mL 4/25/2023

    A customer experienced expensive project delays when they selected their “tried and tested” large volume, glass syringe system to package a drug to be used in an auto-injector for self-administration.

  8. Bringing A Biosimilar For Oncology To Market: Injectable Packaging From Early Development To Commercialization 2/20/2024

    While in their early-stage development of a mAb biosimilar for oncology treatment, a large biopharmaceuticals company sought a packaging recommendation: a stopper to maintain high-quality standards.

  9. Understanding Risks Of Biologic Drugs And Injectable Drug-Device Combination Products

    As the benefits of delivering biologic drugs as part of a combination product platform are realized, this self-administration trend will continue to grow. From a regulatory perspective, the use of a risk-based approach is foundational.

  10. Reducing Lead Time & Optimizing Costs 8/2/2022

    Explore how the use of this component platform produces significant savings, reduces elastomer SKU complexity, and increases speed to market.